Radiat Oncol Bio Phys 1999 ; 44 : 619 – 625 . 3. Horiot JC . Prophylaxis versus treatment: is there a better way to manage radiotherapy-induced nausea and vomiting? Int J Radiat Oncol Biol Phys 2004 ; 15 : 1018 – 1025 . 4
Search Results
Radiation-Induced Nausea and Vomiting
Susan Urba
Use of Acupuncture in the Control of Chemotherapy-Induced Nausea and Vomiting
Ting Bao
cancer nausea and vomiting . J Clin Oncol 2008 ; 26 : 3903 – 3910 . 2 Hickok JT Roscoe JA Morrow GR . Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of
Communicating About Chemotherapy-Induced Nausea and Vomiting: A Comparison of Patient and Provider Perspectives
John M. Salsman, Steven M. Grunberg, Jennifer L. Beaumont, Miriam Rogers, Diane Paul, Marla L. Clayman, and David Cella
Nausea and vomiting are two of the most common and debilitating side-effects of chemotherapy and can result in significant morbidity and adversely impact patient quality of life. 1 – 4 Nausea and vomiting secondary to chemotherapy may lead to
Obstacles to the Implementation of Antiemetic Guidelines
Steven M. Grunberg
. 8 American Society of Health-System Pharmacists . ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery . Am J Health
Are All 5-HT3 Receptor Antagonists the Same?
Robert McNulty
1998 ; 4 : 52 – 58 . 9. Perez EA Hesketh P Sandbach J . Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double
Biobehavioral Factors in Chemotherapy-Induced Nausea and Vomiting
Joseph A. Roscoe, Gary R. Morrow, Jane T. Hickok, Karen M. Mustian, and Abhay R. Shelke
and Prochlorperazine in patients with chemotherapy-induced nausea and vomiting . N Engl J Med 1981 ; 305 : 905 – 909 . 3 Morrow GR Roscoe JA Hickok JT . Nausea and Vomiting . In: Holland JC. , ed. Psycho-oncology. New York : Oxford
Behavioral Interventions in Treating Anticipatory Nausea and Vomiting
Colmar Figueroa-Moseley, Pascal Jean-Pierre, Joseph A. Roscoe, Julie L. Ryan, Sadhna Kohli, Oxana G. Palesh, Elizabeth P. Ryan, Jennifer Carroll, and Gary R. Morrow
The authors have been supported by Grant U10CA 37420 from the National Cancer Institute. References 1. Osoba D Zee B Warr D . Effect of postchemotherapy nausea and vomiting on health-related quality of life . The Quality of
Cannabinoids in the Treatment of Chemotherapy-Induced Nausea and Vomiting
Barbara Todaro
The management of chemotherapy-induced nausea and vomiting (CINV) has improved over the past 20 years. Before the introduction of 5-hydroxytryptamine (5-HT3) receptor antagonists, treatment options were limited to less-effective and more
Corticosteroids in the Treatment of Chemotherapy-Induced Nausea and Vomiting
Sally Yowell Barbour
agents associated with high rates of CINV Analyze the use of corticosteroids in the treatment of acute CINV Analyze the use of corticosteroids in the treatment of delayed CINV Chemotherapy-induced nausea and vomiting (CINV) is one of the most
BPI19-019: Avoidable Acute Care Use Associated With Nausea and Vomiting Among Patients Receiving Highly Emetogenic Chemotherapy or Oxaliplatin
Eric J Roeland, Thomas W. LeBlanc, Kathryn J. Ruddy, Ryan Nipp, Rebecca Clark-Snow, Rita Wickham, Gary Binder, William L. Bailey, Ravi Potluri, Luke M. Schmerold, Eros Papademetriou, and Rudolph M. Navari
department (ED) events (IP/ED) as “potentially avoidable” if involving any of 10 toxicities, including nausea or vomiting (NV). Evidence demonstrates meaningful gaps in oncologists’ adherence to antiemetic prophylaxis guidelines for highly emetogenic
